Form 4: Avid Bioservices Director Catherine Mackey Disposes of Shares and Options in Merger

Director Catherine Mackey reports the disposal of Avid Bioservices shares, stock options, and restricted stock units due to the merger with Space Mergerco, Inc.

Summary

• Catherine Mackey, a director of Avid Bioservices, Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• The filing reports transactions occurring on February 5, 2025, related to the merger of Space Mergerco, Inc. with Avid Bioservices.
• Mackey disposed of 43,379 shares of common stock, stock options for 32,100 shares (at $6.38), 19,675 shares (at $6.87), and 10,030 shares (at $10.72), and 8,147 restricted stock units.
• These disposals were a result of the merger agreement where each share of common stock was converted into the right to receive $12.50 in cash.
• Vested stock options were converted into the right to receive a cash payment equal to the difference between $12.50 and the exercise price, multiplied by the number of shares.
• Unvested restricted stock units were converted into the right to receive a cash payment of $12.50 per share.
• Following these transactions, Mackey's direct ownership of common stock, stock options, and restricted stock units is now zero.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports factual information about the merger and the resulting transactions. There are no explicit positive or negative implications for the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

This announcement reflects a consolidation event in the CDMO (Contract Development and Manufacturing Organization) industry, where Avid Bioservices is being acquired. Such mergers can be driven by factors like economies of scale, market access, or strategic realignment.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as it is a specific event (merger) rather than a performance report.
• However, mergers and acquisitions are common in the biopharmaceutical and CDMO industries, often driven by the desire to expand capabilities or market share.
• Comparable companies that have been involved in similar transactions include Catalent, Thermo Fisher Scientific, and Lonza.

Stakeholder Impact

• Shareholders received $12.50 per share as part of the merger agreement.
• Employees' stock options and restricted stock units were cashed out as per the merger terms.
• The merger may impact the company's future operations and strategic direction.

Key Dates

Keywords

Form 4, Avid Bioservices, Catherine Mackey, Merger, Space Mergerco, Beneficial Ownership, Stock Options, Restricted Stock Units, CDMO